1933 Industries Inc (TGIFF)
0.0106
0.00 (0.00%)
USD |
OTCM |
May 16, 16:00
1933 Industries Enterprise Value: 5.829M for May 16, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 16, 2024 | 5.829M |
| May 15, 2024 | 5.756M |
| May 14, 2024 | 6.246M |
| May 13, 2024 | 6.786M |
| May 10, 2024 | 5.854M |
| May 09, 2024 | 7.718M |
| May 08, 2024 | 6.810M |
| May 07, 2024 | 6.810M |
| May 06, 2024 | 7.718M |
| May 03, 2024 | 7.007M |
| May 02, 2024 | 7.669M |
| May 01, 2024 | 5.903M |
| April 30, 2024 | 5.805M |
| April 29, 2024 | 5.265M |
| April 26, 2024 | 6.295M |
| April 25, 2024 | 6.148M |
| April 24, 2024 | 6.737M |
| April 23, 2024 | 6.737M |
| April 22, 2024 | 6.001M |
| April 19, 2024 | 6.001M |
| April 18, 2024 | 7.963M |
| April 17, 2024 | 7.522M |
| April 16, 2024 | 7.522M |
| April 15, 2024 | 6.590M |
| April 12, 2024 | 7.522M |
| Date | Value |
|---|---|
| April 11, 2024 | 7.718M |
| April 10, 2024 | 7.718M |
| April 09, 2024 | 6.197M |
| April 08, 2024 | 6.492M |
| April 05, 2024 | 8.159M |
| April 04, 2024 | 7.767M |
| April 03, 2024 | 7.571M |
| April 02, 2024 | 5.707M |
| April 01, 2024 | 6.001M |
| March 28, 2024 | 7.080M |
| March 27, 2024 | 6.982M |
| March 26, 2024 | 6.982M |
| March 25, 2024 | 6.344M |
| March 22, 2024 | 6.467M |
| March 21, 2024 | 6.050M |
| March 20, 2024 | 6.050M |
| March 19, 2024 | 5.511M |
| March 18, 2024 | 5.511M |
| March 15, 2024 | 5.020M |
| March 14, 2024 | 4.726M |
| March 13, 2024 | 4.726M |
| March 12, 2024 | 4.579M |
| March 11, 2024 | 6.344M |
| March 08, 2024 | 6.099M |
| March 07, 2024 | 6.050M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
4.530M
Minimum
Jan 31 2024
100.40M
Maximum
May 24 2019
23.69M
Average
18.79M
Median
Enterprise Value Benchmarks
| Acasti Pharma Inc | 0.8274M |
| Aurinia Pharmaceuticals Inc | 474.73M |
| Edesa Biotech Inc | 11.74M |
| Lexaria Bioscience Corp | 35.30M |
| Xenon Pharmaceuticals Inc | 2.345B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.5488M |
| Revenue (Quarterly) | 3.513M |
| Total Expenses (Quarterly) | 3.702M |
| EPS Diluted (Quarterly) | -0.0012 |
| Gross Profit Margin (Quarterly) | 29.61% |
| Profit Margin (Quarterly) | -15.62% |
| Earnings Yield | -226.3% |
| Normalized Earnings Yield | -155.80 |